Metformin fails to show cardiovascular benefit in heart failure trial
Metformin did not significantly affect the risk of cardiovascular outcomes in patients suffering from heart failure with a reduced ejection fraction who had diabetes or were at…
Metformin did not significantly affect the risk of cardiovascular outcomes in patients suffering from heart failure with a reduced ejection fraction who had diabetes or were at…
The TIME-HF trial, presented at the European Society of Cardiology (ESC) Congress 2026, demonstrated that a nurse-coordinated, technology-enabled care model significantly improved…